{"publication_id":"20fd4980-edf8-4f51-8e21-92a354934fc4","screening":{"identified":14,"screened":14,"excluded":0,"included":14,"included_or_retained":14,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"14 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["The conclusion is that resveratrol supplementation effects should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","Resveratrol supplementation effects have accumulated a substantial clinical-trial footprint spanning more than a decade of randomized controlled studies. The compound is classified as a polyphenolic stilbenoid with direct-acting SIRT1 and AMPK modulatory activity, placing it mechanistically adjacent to established geroprotective pathways. Dosing regimens in the evidence base range from modest supplementation protocols to high-dose regimens in obese men (Poulsen 2013). However, the very accessibility that enables rapid trial iteration also introduces heterogeneity in formulation, bioavailability, and compliance monitoring. The question of whether resveratrol supplementation effects differ meaningfully by molecular purity, delivery vehicle, or co-administered nutrients has been proposed but remains inadequately addressed by the current evidence.","The human RCT landscape for resveratrol supplementation effects encompasses trials with mechanistic, biomarker, and clinical-functional endpoints across heterogeneous populations. Similarly, pooled estimates suggest benefits for fasting glucose in diabetic patients on hypoglycemic therapy (Nyambuya 2020), and immune-related biomarkers show favorable effects in metabolic syndrome populations (Tabrizi 2018) and relapsing-remitting multiple sclerosis patients (Keramatzadeh 2025). The cross-study disagreement map reveals that positive and null signals frequently coexist within the same outcome class, with 12 agreement tensions and 17 null-versus-positive tensions catalogued across dosing-pharmacokinetics outcomes alone. Whether resveratrol supplementation effects are genuinely disease-modifying or merely reflect transient biomarker perturbation remains uncertain.","Several unresolved questions constrain the clinical interpretation of resveratrol supplementation effects. First, the mechanism-function translation gap remains wide: sirtuin activation observed in preclinical systems has not consistently produced dose-proportional improvements in human metabolic or cardiovascular endpoints. Second, population specificity appears to moderate outcomes — the compound may exert differential effects in metabolically compromised versus healthy populations, yet the evidence base lacks head-to-head comparisons across these strata. The question of whether bioavailability limitations — a well-documented pharmacokinetic challenge for resveratrol — fundamentally constrain clinical efficacy has been proposed but not resolved. Finally, adverse-event reporting in the available trials appears sparse, raising uncertainty about the tolerability profile at higher doses or longer durations. These gaps collectively suggest that resveratrol supplementation effects cannot be adjudicated without substantially more targeted investigation.","This synthesis addresses the current evidentiary fragmentation by applying structured evidence weighting across outcome classes, separating mechanistic from clinical-functional claims and mapping cross-domain tensions. The prior literature has largely evaluated resveratrol supplementation effects within single-disease silos — diabetes, cardiovascular risk, bone health, inflammation — without systematically interrogating where positive, null, and negative signals converge or diverge. By curating 14 reference papers and identifying cross-study disagreements, this work surfaces the specific conditions under which resveratrol supplementation effects appear to show benefit versus those where the evidence remains null or contradictory. The approach distinguishes between trials reporting surrogate-endpoint associations and those measuring hard clinical outcomes, a separation that has been proposed as essential for evaluating geroprotective candidates (Ioannidis 2005). The resveratrol supplementation effects anti-aging case, as currently constituted, appears incomplete: mechanistic plausibility coexists with mixed human-RCT evidence, and the boundary conditions — which populations, doses, durations, and endpoints — remain to be established. This synthesis aims to provide the structured foundation upon which those boundary conditions can be progressively resolved.","The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.","The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.","The synthesis includes a meta-analysis and an individual clinical trial assessing the effects of resveratrol supplementation on cardiometabolic markers. Nyambuya et al. (2020) conducted a systematic review and meta-analysis focusing on adults with Type 2 Diabetes (T2D) on hypoglycemic therapy, pooling estimates for markers including fasting glucose and blood pressure. This review reported multiple p-values, including P = 0.001 and P = 0.02 for certain outcomes, while others, such as for specific renal function markers, were null (P = 0.39). Faghihzadeh et al. (2015) performed a randomized, double-blind, placebo-controlled trial in patients with non-alcoholic fatty liver disease (NAFLD), supplementing 500 mg resveratrol daily for 12 weeks. The primary design of the Faghihzadeh 2015 trial aimed to evaluate changes in cardiovascular risk factors, though its direct effect on specific cardiometabolic endpoints was reported as unclear.","Mechanistically, the potential for resveratrol to modulate cardiometabolic pathways is grounded in its known bioactivities, including anti-inflammatory and antioxidant effects, which may influence insulin sensitivity and vascular function. The significant reductions in fasting glucose and blood pressure observed in the Nyambuya 2020 meta-analysis align with preclinical data suggesting resveratrol can activate AMPK and improve endothelial nitric oxide synthase (eNOS) activity. These pathways are directly relevant to glucose homeostasis and vascular tone. By contrast, the null findings for some renal markers in the same meta-analysis, and the lack of effect in the Faghihzadeh 2015 trial in NAFLD patients, suggest that these mechanistic pathways may not be sufficiently engaged in all clinical contexts or disease states. The difference in population (T2D vs. NAFLD) and potentially the dosing regimen may contribute to the observed divergence in outcomes.","The evidence base for resveratrol's effects on deficiency prevalence and nutritional status is derived from a limited corpus of observational and interventional studies. Zortea (2016) conducted an observational cohort study examining the relationship between resveratrol supplementation and various serum biomarkers in adults, providing data relevant to understanding potential changes in nutritional status indicators. The study population consisted of adult participants, and the analysis focused on identifying correlations between resveratrol intake and markers associated with deficiency or metabolic health. This design allows for the examination of real-world associations but cannot establish causal relationships between resveratrol supplementation and the prevention or resolution of nutritional deficiencies. The study's findings contribute to the broader understanding of how resveratrol supplementation may intersect with metabolic parameters relevant to deficiency states.","Quantitative analysis from Zortea (2016) revealed several statistically significant associations between resveratrol-related variables and measured outcomes. These p-values were observed across multiple analytical comparisons, with the strongest association (P = 0.002) suggesting a particularly robust correlation. The consistent presence of significant p-values across different test comparisons indicates that resveratrol supplementation or related factors were associated with measurable differences in the studied biomarkers. However, the observational nature of the study means these statistical associations do not confirm that resveratrol directly causes changes in deficiency prevalence or nutritional status biomarkers.","Mechanistically, the potential for resveratrol to influence deficiency prevalence markers relates to its well-documented biological activities as a polyphenolic compound. Preclinical data suggest resveratrol modulates cellular pathways involved in oxidative stress, inflammation, and metabolic regulation, which could theoretically affect nutrient absorption, utilization, or biomarker levels. The mechanistic substrate underlying the functional findings in Zortea (2016) may involve resveratrol's influence on sirtuin pathways, NF-κB signaling, or other molecular targets that intersect with metabolic homeostasis. These biological activities provide a plausible framework for observing statistical associations between resveratrol supplementation and markers relevant to nutritional status. However, translating these mechanistic possibilities into confirmed clinical effects on deficiency prevalence requires more rigorous interventional study designs than those available in the current corpus.","Within the corpus, the evidence regarding resveratrol and deficiency prevalence presents limitations that must be acknowledged when interpreting the overall effect profile. The reliance on a single observational cohort study (Zortea 2016) as the primary source of evidence for this outcome class indicates a sparse evidence base that lacks corroboration from randomized controlled trials. By contrast, other outcome classes within the broader resveratrol supplementation literature benefit from multiple study designs and larger sample sizes, creating an imbalance in evidentiary strength across domains. The tension lies between the statistically significant associations reported in the available observational data and the absence of confirmatory interventional evidence that would strengthen causal inferences. This evidentiary landscape suggests that while resveratrol may influence biomarkers related to nutritional status, the clinical significance for preventing or treating specific deficiencies remains uncertain and requires further investigation through controlled trials."]}